$FTLF

FitLife Brands posts Q4 revenue surge to $25.9M after Irwin acquisition; Q4 adjusted EBITDA $3.5M

FitLife Brands reported a significant increase in its fourth-quarter revenue, reaching $25.9 million, primarily due to the acquisition of Irwin. The company also posted a Q4 adjusted EBITDA of $3.5 million, marking a 14% year-over-year increase. While legacy FitLife organic revenue grew for the year, Q4 legacy revenue saw a decline.

Original reporting
Published Apr 8, 2026, 12:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 8, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$FTLF
Bullish
medium confidence
Mentioned
$FTLF
alphai data visualization · based on TradingView
Decision brief

The 30-second read

$FTLFBullishMed
01

Why it matters

The acquisition appears to have positively impacted revenue and EBITDA, but the decline in legacy revenue warrants caution.

02

Market read

The news is relevant for investors interested in the consumer health sector, indicating potential growth opportunities.

03

What to watch

Integration costs and market competition may dampen the long-term benefits of the acquisition.

Timing: Immediate, as earnings and acquisition details are recent.

Background

FitLife Brands acquired Irwin, a strategic move to expand product offerings and market share, leading to a revenue surge in Q4.

Company-level read

Ticker impact

$FTLFBullishMedium confidence
Context

The news highlights a revenue increase primarily driven by an acquisition, with a modest organic growth. The positive earnings report and acquisition activity suggest potential short- to medium-term bullishness.

Expected impact

Moderate upward movement in the near term, with potential for continued growth if acquisition benefits are realized.

Evidence & confidence

The revenue boost and EBITDA growth support a bullish outlook, but the decline in legacy revenue introduces some caution. The overall sentiment remains positive, but the sustainability depends on integration success and organic growth recovery.

Market effects

Potential positive sentiment in the consumer health and wellness sector due to acquisition and revenue growth.

Limited regional impact; primarily relevant to North American markets where FitLife operates.

Low; company-specific news with limited global implications.

Counterpoint

The decline in legacy revenue could signal underlying challenges, risking future profitability.

Key entities

  • FitLife Brands

    A health and wellness product company.

  • Irwin

    A company acquired to expand FitLife's product portfolio.

Related articles

$FTLFMed

FitLife Brands (FTLF) Q2 2026 Earnings Call Transcript

FitLife Brands (FTLF) reported Q2 2026 earnings. Legacy FitLife's gross margin rose to 41.7%, but contribution fell 25.9% to $4.2M. Irwin's revenue hit $14.1M, with Amazon sales growing. The company is improving supply chain, product development, and marketing. SG&A costs dropped 3.8% sequentially. The term loan balance is $36.1M, with $8.6M of debt paid since the Irwin acquisition.

$FTLFMed

FitLife Brands Q2 Earnings Call Highlights

FitLife Brands (NASDAQ:FTLF) reported Q2 call highlights. Irwin direct Amazon sales rose from about $500k monthly in Dec 2025 to about $1m in June 2026, with July comparable to June. Legacy revenue fell 23% YoY to $12.4m; gross margin 41.7%. FitLife is extending Irwin shelf life and launching new products. It paid about $1.5m term-loan, cutting term-loan to $36.1m.

$FTLFMed

FITLIFE BRANDS, INC. (FTLF): Results of Operations and Financial Condition

FITLIFE BRANDS, INC. (FTLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FitLife Brands Announces Second Quarter 2026 Results OMAHA, NE – August 13, 2026 – FitLife Brands, Inc. (“ FitLife ” or the “ Company ”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.